Similarly, lenalidomide (Revlimid) has been shown to induce >2-fold increase in SPARC expression in cultured cells isolated from patients with myelodysplastic syndromes, which may explain the anti-proliferative, anti-adhesion, and anti-angiogenic properties of this drug (57–59). Here, SPARC is linked to myelodysplastic syndrome.